Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 12,170
  • Shares Outstanding, K 365,470
  • Annual Sales, $ 5,520 K
  • Annual Income, $ -3,480 K
  • 36-Month Beta 6.42
  • Price/Sales 2.20
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/15/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0220 +50.00%
on 05/10/18
0.0615 -46.34%
on 05/02/18
-0.0227 (-40.75%)
since 04/25/18
3-Month
0.0220 +50.00%
on 05/10/18
0.0880 -62.50%
on 04/09/18
-0.0085 (-20.48%)
since 02/23/18
52-Week
0.0160 +106.25%
on 08/29/17
0.1145 -71.18%
on 05/30/17
-0.0710 (-68.27%)
since 05/25/17

Most Recent Stories

More News
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science...

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer, Dr. Kristin Comella, Featured on Health Boot Camps' Webinar

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer,...

USRM : 0.0330 (-0.90%)
U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine...

USRM : 0.0330 (-0.90%)
U.S. Stem Cell Reports First Quarter Results

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0330 (-0.90%)
U.S. Stem Cell Reports First Quarter Results

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced first quarter results for 2018....

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer to Host Webinar on Autologous Stem Cell Therapy

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0330 (-0.90%)
USRM Chief Science Officer Featured in Live Interview for Biohacker Summit in Helsinki

MIAMI , May 3, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announced...

USRM : 0.0330 (-0.90%)
Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced sales figures for 2016 and 2017...

USRM : 0.0330 (-0.90%)
USRM Announces 2017 Financial Results

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today filed a Form 10-K reporting year-end numbers...

USRM : 0.0330 (-0.90%)
Newest Clinic Opens Today at The Villages in Central Florida

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening its first USRM clinic...

USRM : 0.0330 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade USRM with:

Key Turning Points

2nd Resistance Point 0.0353
1st Resistance Point 0.0342
Last Price 0.0330
1st Support Level 0.0317
2nd Support Level 0.0303

See More

52-Week High 0.1145
Fibonacci 61.8% 0.0769
Fibonacci 50% 0.0653
Fibonacci 38.2% 0.0536
Last Price 0.0330
52-Week Low 0.0160

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar